Related Experiment Video
Updated: May 21, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
Andy Hsu1, David S Ritchie, Paul Neeson
1Haematology and Immunology Translational Research Laboratory; Peter MacCallum Cancer Centre; St Andrews Place; East Melbourne, Australia.
Abstract:
Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease.
Related Concept Videos
Drug Toxicity: Dose-Dependent Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Toxicity: Allergic Reactions
Desensitization and Tachyphylaxis
Several...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
